Calton & Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Calton & Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,500	Closed	-$220K	–	360
2021 Q4	$220K	Buy	+2,500	New	+$206K	0.06%	330
2021 Q3	–	Sell	-2,526	Closed	-$211K	–	403
2021 Q2	$211K	Buy	+2,526	New	+$200K	0.04%	377
2021 Q1	–	Sell	-2,607	Closed	-$229K	–	404
2020 Q4	$229K	Buy	+2,607	New	+$207K	0.04%	335
2020 Q3	–	Sell	-1,693	Closed	-$209K	–	350
2020 Q2	$209K	Buy	+1,693	New	+$168K	0.05%	297
2018 Q1	–	Sell	-43	Closed	-$3K	–	449
2017 Q4	$3K	Buy	+43	New	+$3.74K	﹤0.01%	1306

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Calton & Associates's BMRN Position: Q1 2022 in Review

Calton & Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 2,500 shares — an estimated $220K sold.

Calton & Associates first reported a position in BMRN in Q4 2017 and held it in 5 quarters. The position peaked at $229K in Q4 2020. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Calton & Associates reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Calton & Associates sold 2,500 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $220K.
Calton & Associates first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 5 quarters.
Calton & Associates's BioMarin Pharmaceuticals position peaked at $229K in Q4 2020.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Calton & Associates's 13F filing for Q1 2022, filed 12 Apr 2022.